Ipsen: sales up 11% in Q1
Growth excluding currency effects was driven by the performance of growth platforms, up 16.2%, and a growing contribution from new drugs, while Somatuline sales fell by just 1.3%.
Ipsen confirms its 2024 targets (excluding the potential impact of additional external late-stage product innovation transactions) of sales growth in excess of 6% at constant exchange rates and an operating margin of around 30%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction